Scancell Holdings – executive interview

In this interview, we discuss with Scancell Holdings’ chief medical officer, Dr Nermeen Varawalla, the evolving immune oncology landscape and the increasingly important role of therapeutic vaccines, in particular as combination treatments with immune checkpoint inhibitors (ICIs). Nermeen also highlights the company’s two distinct vaccine platforms and the recently presented promising Phase II data from Scancell’s lead asset iSCIB1+ in advanced melanoma, which supports accelerated progression to Phase III trials in 2026. Nermeen ended the interview outlining the upcoming catalysts for the company in the next 12– 18 months.

Scancell Holdings (AIM: SCLP) is a UK-based clinical-stage biotech company developing off-the-shelf active immunotherapies against cancer using two proprietary platforms, ImmunoBody (DNA vaccines) and Moditope (peptide vaccines). Its lead candidate from the ImmunoBody platform, iSCIB1+, has reported promising Phase II data in advanced melanoma, with clear synergies when combined with ICIs. Its lead asset from the Moditope platform, Modi-1, is being tested in solid tumours.